Taken together, these findings establish HSP90, and particularly HSP90B1, as a prognostic biomarker and a functional DAMP in ccRCC, whose targeting may not only disrupt tumor cell homeostasis but also reprogram the tumor immune microenvironment toward enhanced immunogenicity [96]. Here, HSP90B1 is linked to neoplasm.